KMT2D and leukemia: Then, since KMT2D is a writer of H3K4 mono‐ and di‐methylation, we also noticed the consistent reduction of H3K4me1 and H3K4me2 levels in leukemia cells with Kmt2d knockdown, indicating on‐target effects of shKmt2d (Figure 1J).